Loading
Life sciences · Journal article
The Korean Society for Veterinary Nursing · September 21, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Fecal microbiota transplantation (FMT) is receiving increasing attention as a microbiome-directed adjunctive therapy for canine gastrointestinal diseases, and clinical research has expanded in dogs with acute diarrhea, canine parvoviral enteritis, antimicrobial-associated dysbiosis, and chronic enteropathy (CE). Current evidence suggests that FMT may improve fecal consistency and clinical disease activity, promote recovery of microbial balance, and contribute to the restoration of bile acid conversion and short-chain fatty acid metabolism. Favorable clinical responses have been reported following rectal administration, whereas oral capsules and lyophilized formulations may offer practical advantages for repeated treatment, storage, transport, and outpatient administration. However, differences in study design and recipient populations preclude conclusions regarding the superiority of any administration route. Although existing studies vary in patient characteristics, disease definitions, product formulation, dose, administration route, and treatment frequency, their findings support the continued development of FMT as a microbiome-based therapeutic option. Further progress will require standardized donor qualification, infectious-disease and antimicrobial-resistance screening, reproducible manufacturing and quality-control procedures, product traceability, and systematic adverse-event monitoring. With the establishment of evidence-based clinical protocols, quality standards, and appropriate regulatory oversight, FMT has considerable potential to become a safe and effective adjunctive therapy for canine gastrointestinal diseases.